CD38 and acute myeloid leukemia: Gurney et al., followed a similar approach to target primary AML blasts in vitro using CAR-NK cells expressing an affinity-optimized CD38 CAR and further engineered with CD38 knockdown, given its expression in both AML and expanded NK cells [79,80].